{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T09:47:13Z","timestamp":1789811233320,"version":"4.0.1"},"reference-count":41,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2007,7]]},"DOI":"10.1097\/01.ncc.0000281758.85704.9b","type":"journal-article","created":{"date-parts":[[2007,7,18]],"date-time":"2007-07-18T04:03:17Z","timestamp":1184731397000},"page":"S17-S26","source":"Crossref","is-referenced-by-count":24,"title":["Insights Into the Pathophysiology and Management of Dermatologic Toxicities to EGFR-Targeted Therapies in Colorectal Cancer"],"prefix":"10.1097","volume":"30","author":[{"given":"Mario E.","family":"Lacouture","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-3-20210203","first-page":"296","article-title":"Issues and progress with protein kinase inhibitors for cancer treatment.","volume":"2","author":"Dancey","year":"2003","journal-title":"Nat Rev Cancer"},{"key":"R2-3-20210203","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1200\/JCO.2004.11.037","article-title":"Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment.","volume":"22","author":"Grothey","year":"2004","journal-title":"J Clin Oncol"},{"key":"R3-3-20210203","first-page":"249","article-title":"EGF receptors as a target for cancer therapy.","volume":"115","author":"Mendelsohn","year":"2004","journal-title":"Trans Am Clin Climatol Assoc"},{"key":"R4-3-20210203","doi-asserted-by":"crossref","first-page":"27826","DOI":"10.1074\/jbc.M504485200","article-title":"Imaging epidermal growth factor receptor phosphorylation in human colorectal cancer cells and human tissues.","volume":"280","author":"Keese","year":"2005","journal-title":"J Biol Chem"},{"key":"R5-3-20210203","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1200\/JCO.2004.10.182","article-title":"Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor.","volume":"22","author":"Saltz","year":"2004","journal-title":"J Clin Oncol"},{"key":"R6-3-20210203","doi-asserted-by":"crossref","first-page":"2454","DOI":"10.1002\/1097-0142(19930415)71:8<2454::AID-CNCR2820710805>3.0.CO;2-2","article-title":"The prognostic significance of proliferating cell nuclear antigen, epidermal growth factor, and mdr expression in colorectal cancer.","volume":"71","author":"Mayer","year":"1993","journal-title":"Cancer"},{"key":"R7-3-20210203","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/1040-8428(94)00144-I","article-title":"Epidermal growth factor-related peptides and their receptors in human malignancies.","volume":"19","author":"Salomon","year":"1995","journal-title":"Crit Rev Oncol\/Hematol"},{"key":"R8-3-20210203","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1200\/JCO.2002.20.1.110","article-title":"Pharmacodynamic studies of the epidermal growth factor receptor inhibitor ZD1839 in skin from cancer patients: histopathologic and molecular consequences or receptor inhibition.","volume":"20","author":"Albanell","year":"2002","journal-title":"J Clin Oncol"},{"key":"R9-3-20210203","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1038\/nrc1970","article-title":"Mechanisms of cutaneous toxicities to EGFR inhibitors.","volume":"6","author":"Lacouture","year":"2006","journal-title":"Nat Rev Cancer"},{"key":"R10-3-20210203","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1242\/jcs.1993.Supplement_17.28","article-title":"Epidermal differentiation and keratin gene expression.","volume":"17","author":"Fuchs","year":"1993","journal-title":"J Cell Sci Suppl"},{"key":"R11-3-20210203","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1038\/nrc1609","article-title":"ERBB receptors and cancer: the complexity of targeted inhibitors.","volume":"5","author":"Hynes","year":"2005","journal-title":"Nat Rev Cancer"},{"key":"R12-3-20210203","doi-asserted-by":"crossref","first-page":"2363","DOI":"10.1242\/jcs.02346","article-title":"Heparin-binding EGF-like growth factor accelerates keratinocyte migration and skin wound healing.","volume":"118","author":"Shirakata","year":"2005","journal-title":"J Cell Sci"},{"key":"R13-3-20210203","doi-asserted-by":"crossref","first-page":"2681","DOI":"10.1038\/sj.onc.1202631","article-title":"Neuregulin-4: a novel growth factor that acts through the ErbB-4 receptor tyrosine kinase.","volume":"18","author":"Harari","year":"1999","journal-title":"Oncogene"},{"key":"R14-3-20210203","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1111\/1523-1747.ep12874601","article-title":"Immunolocalization of epidermal growth factor receptors in normal developing human skin.","volume":"94","author":"Nanney","year":"1990","journal-title":"J Invest Dermatol"},{"key":"R15-3-20210203","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1200\/JCO.2000.18.4.904","article-title":"Phase I studies of anti-epidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin.","volume":"18","author":"Baselga","year":"2000","journal-title":"J Clin Oncol"},{"key":"R19-3-20210203","doi-asserted-by":"crossref","first-page":"2787","DOI":"10.1200\/JCO.2003.01.504","article-title":"Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer.","volume":"21","author":"Mendelsohn","year":"2003","journal-title":"J Clin Oncol"},{"key":"R20-3-20210203","doi-asserted-by":"crossref","first-page":"4292","DOI":"10.1200\/JCO.2002.03.100","article-title":"Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types.","volume":"20","author":"Baselga","year":"2002","journal-title":"J Clin Oncol"},{"key":"R21-3-20210203","doi-asserted-by":"crossref","first-page":"3815","DOI":"10.1200\/JCO.2002.03.038","article-title":"Selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 is generally well-tolerated and has activity in non-small-cell lung cancer and other solid tumors: results of a phase I trial.","volume":"20","author":"Herbst","year":"2002","journal-title":"J Clin Oncol"},{"key":"R22-3-20210203","doi-asserted-by":"crossref","first-page":"3080","DOI":"10.1200\/JCO.2004.08.189","article-title":"Evaluation of biologic end points and pharmacokinetics in patients with metastatic breast cancer after treatment with erolotinib, an epidermal growth factor receptor tyrosine kinase inhibitor.","volume":"22","author":"Tan","year":"2004","journal-title":"J Clin Oncol"},{"key":"R23-3-20210203","first-page":"2478","article-title":"Pharmacodynamic evaluation of the epidermal growth factor receptor inhibitor OSI-774 in human epidermis of cancer patients.","volume":"9","author":"Malik","year":"2003","journal-title":"Clin Cancer Res"},{"key":"R24-3-20210203","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1242\/jcs.110.2.113","article-title":"EGF-R dependent regulation of keratinocyte survival.","volume":"110","author":"Rodeck","year":"1997","journal-title":"J Cell Sci"},{"key":"R25-3-20210203","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1046\/j.1365-2133.2001.04226.x","article-title":"Cutaneous side-effects in cancer patients treated with the antiepidermal growth factor receptor antibody C225.","volume":"144","author":"Busam","year":"2001","journal-title":"Br J Dermatol"},{"key":"R26-3-20210203","first-page":"505","article-title":"The EGF receptor-an essential regulator of multiple epidermal functions.","volume":"10","author":"Jost","year":"2000","journal-title":"Eur J Dermatol"},{"key":"R27-3-20210203","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/S0002-9440(10)63654-1","article-title":"Blockade of the EGF receptor induces a deranged chemokine expression in keratinocytes leading to enhanced skin inflammation.","volume":"163","author":"Mascia","year":"2003","journal-title":"Am J Pathol"},{"key":"R28-3-20210203","doi-asserted-by":"crossref","first-page":"5047","DOI":"10.4049\/jimmunol.174.8.5047","article-title":"ERK1\/2 regulates epidermal chemokine expression and skin inflammation.","volume":"174","author":"Pastore","year":"2005","journal-title":"J Immunol"},{"key":"R29-3-20210203","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1111\/j.1365-2133.2004.06026.x","article-title":"Acneiform eruption induced by epidermal growth factor receptor inhibitors in patients with solid tumors.","volume":"151","author":"Jacot","year":"2004","journal-title":"Br J Dermatol"},{"issue":"1","key":"R30-3-20210203","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1111\/j.1600-0781.2007.00273.x","article-title":"Photosensitive rash due to the epidermal growth factor receptor erlotinib.","volume":"23","author":"Luu","year":"2007","journal-title":"Photodermatol Photoimmunol Photomed"},{"key":"R31-3-20210203","doi-asserted-by":"crossref","first-page":"5235","DOI":"10.1200\/JCO.2005.00.6916","article-title":"Cutaneous adverse effects with HER1\/EFGR-targeted agents: is there a silver lining?","volume":"23","author":"Perez-Soler","year":"2005","journal-title":"J Clin Oncol"},{"key":"R32-3-20210203","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1093\/annonc\/mdi279","article-title":"Clinical signs, pathophysiology and management of skin toxicity during therapy with epidermal growth factor receptor inhibitors.","volume":"16","author":"Segaert","year":"2005","journal-title":"Ann Oncol"},{"key":"R33-3-20210203","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1016\/j.jaad.2005.10.010","article-title":"Dermatologic side effects associated with the epidermal growth factor receptor inhibitors.","volume":"55","author":"Agero","year":"2006","journal-title":"J Am Acad Dermatol"},{"key":"R34-3-20210203","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1634\/theoncologist.10-5-345","article-title":"HER1\/EGFR inhibitor-associated rash: future directions for management and investigation outcomes from the HER1\/EGFR inhibitor rash management forum.","volume":"10","author":"Perez-Soler","year":"2005","journal-title":"Oncologist"},{"key":"R35-3-20210203","doi-asserted-by":"crossref","first-page":"3238","DOI":"10.1200\/JCO.2004.11.057","article-title":"Determinants of tumor response and survival with erlotinib in patients with non-small-cell lung cancer.","volume":"22","author":"Perez-Soler","year":"2004","journal-title":"J Clin Oncol"},{"key":"R36-3-20210203","doi-asserted-by":"crossref","first-page":"2240","DOI":"10.1200\/JCO.2002.10.112","article-title":"ZD1839, a selective oral epidermal growth factor-tyrosine kinase inhibitor, is well tolerated and active in patients with solid, malignant tumors: results of a phase I trial.","volume":"20","author":"Ranson","year":"2002","journal-title":"J Clin Oncol"},{"key":"R37-3-20210203","doi-asserted-by":"crossref","first-page":"3003","DOI":"10.1200\/JCO.2004.11.061","article-title":"Safety, pharmacokinetics, and activity of ABX-EGF, a fully human anti-epidermal growth factor receptor monoclonal antibody in patients with metastatic renal cell cancer.","volume":"22","author":"Rowinsky","year":"2004","journal-title":"J Clin Oncol"},{"key":"R40-3-20210203","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.jaad.2006.04.062","article-title":"Description and management of cutaneous side effects during cetuximab or erlotinib treatments: a prospective study of 30 patients.","volume":"55","author":"Roe","year":"2006","journal-title":"J Am Acad Dermatol"},{"key":"R41-3-20210203","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1111\/j.1365-2133.2006.07452.x","article-title":"The PRIDE (Papulopustules and\/or paronychia, Regulatory abnormalities of hair growth, Itching, and Dryness due to Epidermal growth factor receptor inhibitors) syndrome.","volume":"155","author":"Lacouture","year":"2006","journal-title":"Br J Dermatol"},{"key":"R42-3-20210203","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/S1470-2045(05)70243-6","article-title":"Cutaneous side-effects of kinase inhibitors and blocking antibodies.","volume":"6","author":"Robert","year":"2005","journal-title":"Lancet Oncol"},{"key":"R43-3-20210203","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1111\/j.1365-4632.2005.02185.x","article-title":"Purpuric drug eruption possibly due to gefitinib (Iressa).","volume":"44","author":"Kurokawa","year":"2005","journal-title":"Int J Dermatol"},{"key":"R44-3-20210203","first-page":"236","article-title":"The SERIES clinic: an interdisciplinary approach to the management of toxicities of EGFR inhibitors.","volume":"4","author":"Lacouture","year":"2006","journal-title":"J Support Oncol"},{"key":"R47-3-20210203","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/j.jpainsymman.2006.07.006","article-title":"Efficacy of pregabalin in the management of cetuximab-related itch.","volume":"32","author":"Prozio","year":"2006","journal-title":"J Pain Symptom Manage"},{"key":"R48-3-20210203","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1111\/j.1365-2133.2005.07010.x","article-title":"Doxycycline for the treatment of paronychia induced by the epidermal growth factor receptor cetuximab.","volume":"154","author":"Suh","year":"2006","journal-title":"Br J Dermatol"}],"container-title":["Cancer Nursing"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/01.NCC.0000281758.85704.9b","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T16:48:48Z","timestamp":1786034928000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00002820-200707001-00003"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,7]]},"references-count":41,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2007]]}},"URL":"https:\/\/doi.org\/10.1097\/01.ncc.0000281758.85704.9b","relation":{},"ISSN":["0162-220X"],"issn-type":[{"value":"0162-220X","type":"print"}],"subject":[],"published":{"date-parts":[[2007,7]]}}}